CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced further details of
oral and poster presentations at the American Society of Clinical
Oncology’s (ASCO) ASCO20 Virtual Scientific Program taking place
from May 29 - May 31, 2020.
Presentation titles, presenters and timing are listed below with
all abstracts available at the ASCO20 Meeting Library.
CytomX’s ASCO20 clinical presentations for CX-072 (Abstract
3005), CX-2009 (Abstract 526) as well as CX-2029 (Abstract 3502),
developed in partnership with AbbVie, will have data cutoff dates
of approximately five months later than the abstract data cutoff.
All presentations will be available on Friday, May 29, 2020 8:00 am
EDT.
“Our upcoming presentations at ASCO highlight the broad progress
that has been made across our clinical stage portfolio and the
potential of our Probody platform,” said Alison L. Hannah, M.D.,
chief medical officer of CytomX Therapeutics. “We look forward to
sharing this comprehensive update that includes the first clinical
data for CX-2029, a first in class Probody Drug Conjugate targeting
CD71, as well as new data to support CX-2009 moving into later
stage trials in breast cancer. These and other programs in
our pipeline, including CX-072, a Probody checkpoint inhibitor and
BMS-986249, the anti-CTLA-4 Probody therapeutic being developed in
collaboration with Bristol Myers Squibb have the potential to
deliver meaningful advances for patients with cancer.”
Abstract 3502 CX-2029, a PROBODY Drug Conjugate
Targeting CD71 (Transferrin Receptor): Results from a
First-in-Human Study (PROCLAIM-CX-2029) in Patients (Pts) With
Advanced Cancer Presenter: Melissa L. Johnson,
M.D., Sarah Cannon Research Institute at Tennessee Oncology,
Nashville Session Title: Developmental
Therapeutics—Immunotherapy Session Date and Time:
Friday, May 29, 2020 8:00 am EDT Session Type:
Oral Presentation
Abstract 526 Poster 18
CX-2009, A CD166-Directed PROBODY Drug Conjugate (PDC): Results
From the First-in-Human Study in Patients With Advanced Cancer
Including Breast Cancer Presenter: Valentina Boni,
M.D., Ph. D., START Madrid – CIOCC, Madrid, Spain Session
Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Friday, May 29, 2020 8:00
am EDT Session Type: Poster Presentation
Abstract 3599 Poster 329
Preliminary Clinical Pharmacokinetics and Dose-Response to Support
a Phase 2 Dose Selection for CX-2009: A Masked PROBODY Drug
Conjugate to CD166 Presenter: Mark Stroh, Ph.D.,
CytomX Therapeutics Session Title: Developmental
Therapeutics—Immunotherapy Session Date and Time:
Friday, May 29, 2020 8:00 am EDT Session Type:
Poster Presentation
Abstract 3005 PROCLAIM-CX-072: Analysis of
Patients With Advanced Solid Tumors Receiving Long-Term Treatment
With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in
Combination With Ipilimumab Presenter: Fiona C.
Thistlethwaite, MB, MChir, Ph.D, The Christie NHS Foundation Trust,
University of Manchester, United Kingdom Session
Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Friday, May 29, 2020 8:00
am EDT Session Type: Oral Presentation
Abstract 3108 Poster 172 Evidence
of Intratumoral Localization, Activation, and Immunomodulatory
Effect of CX-072, a PROBODY Therapeutic Targeting PD-L1, in a Phase
1/2 Trial Presenter: Susan K. Lyman, CytomX
Therapeutics Session Title: Developmental
Therapeutics—Immunotherapy Session Date and Time:
Friday, May 29, 2020 8:00 am EDT Session Type:
Poster Presentation
Abstract 3602 Poster 332
Preliminary Population Pharmacokinetics Supports Phase 2 Dose
Selection for Masked Anti–PD-L1 Antibody CX-072
Presenter: Mark Stroh, Ph.D., CytomX Therapeutics
Session Title: Developmental
Therapeutics—Immunotherapy Session Date and Time:
Friday, May 29, 2020 8:00 am EDT Session Type:
Poster Presentation
Abstract 3058 Poster 122
Anti–CTLA-4 probody BMS-986249 Alone or in Combination with
Nivolumab in Patients with Advanced Cancers: Initial Phase 1
Results Presenter: Martin Gutierrez, M.D.
Hackensack University Medical Center, Hackensack, New Jersey
Session Title: Developmental
Therapeutics—Immunotherapy Session Date and Time:
Friday, May 29, 2020 8:00 am EDT Session Type:
Poster Presentation
About CytomX Therapeutics CytomX is a
clinical-stage, oncology-focused biopharmaceutical company with a
vision of transforming lives with safer, more effective therapies.
We are developing a novel class of investigational antibody
therapeutics, based on our Probody® technology platform, for
the treatment of cancer. Probody therapeutics are designed to
remain inactive until they are activated by proteases in the tumor
microenvironment. As a result, Probody therapeutics are intended to
bind selectively to tumors and decrease binding to healthy tissue,
to minimize toxicity and potentially create safer, more effective
therapies. As leaders in the field, our innovative technology is
designed to turn previously undruggable targets into druggable
targets and to enable more effective combination therapies. CytomX
and its partners, comprised of leading biotechnology and
pharmaceutical companies, have developed a robust pipeline of
potential first-in-class therapeutic candidates against novel,
difficult to drug targets and potential best-in-class
immunotherapeutic candidates against clinically validated targets.
The CytomX clinical stage pipeline includes first-in-class product
candidates against previously undruggable targets, including a
CD166-targeting Probody drug conjugate wholly owned by CytomX
(CX-2009) and a CD71-targeting Probody drug conjugate partnered
with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that
are considered to be inaccessible to conventional antibody drug
conjugates due to their presence on many healthy tissues. The
CytomX clinical stage pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb. CytomX has strategic drug
discovery and development collaborations with AbbVie, Amgen,
Astellas and Bristol Myers Squibb. For additional information
about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking
Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements, including those relating to
the potential benefits, safety and efficacy or progress of CytomX’s
or any of its collaborative partners’ product candidates, the
potential benefits or applications of CytomX’s Probody platform
technology, and CytomX’s ability to develop and advance product
candidates into and successfully complete clinical trials,
including the ongoing and planned clinical trials of CX-2009 and
CX-2029. Risks and uncertainties that contribute to the uncertain
nature of the forward-looking statements include: the unproven
nature of CytomX’s novel Probody Platform technology; CytomX’s
clinical trial product candidates are in the initial stages of
clinical development and its other product candidates are currently
in preclinical development, and the process by which preclinical
and clinical development could potentially lead to an approved
product is long and subject to significant risks and uncertainties,
including the risk that the COVID-19 worldwide pandemic may
continue to negatively impact the business, research and clinical
operations of CytomX or its partners, including the development of
preclinical drug candidates due to delays in and disruption of
research activities and the development of clinical drug candidates
due to delays in or disruption of clinical trials, including
impacts on the enrollment of patients in clinical trials or other
clinical trial disruptions; the possibility that the results of
early clinical trials may not be predictive of future results; the
possibility that CytomX’s clinical trials will not be successful;
the possibility that current pre-clinical research may not result
in additional product candidates; CytomX’s dependence on the
success of CX-2009, CX-2029, BMS-986249 and BMS-986288; CytomX’s
reliance on third parties for the manufacture of the company’s
product candidates; and possible regulatory developments in the
United States and foreign countries. Additional applicable
risks and uncertainties include those relating to our preclinical
research and development, clinical development, and other risks
identified under the heading "Risk Factors" included in CytomX’s
Quarterly Report on Form 10-Q filed with the SEC on May 7, 2020.
The forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
Investor and Media Contact: Christopher Keenan VP, Investor
Relations and Corporate Communications
ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024